Clinical-stage psychedelics company developing LSD-based therapies for major depressive disorder and other psychiatric conditions.
Company Info
Upcoming Milestones & Key Dates
Phase 3 topline data (DT-120 MDD)
NDA submission for DT-120
Clinical Development Pipeline
Recent News
Definium Therapeutics reported Phase 3 results showing its LSD-based therapy elicited 'profound' efficacy in treatment-resistant depression, marking a notable psychedelic-pharma readout.
Definium Therapeutics' LSD-based therapy showed 'profound' efficacy in a late-stage trial in major depressive disorder.
Leadership Team
Chief Executive Officer
Careers & Job Openings